IL22 and myocardial infarction: It has been shown that injection of MI mice with recombinant interleukin (IL)-22 in the 1st week after acute MI effectively prevents left ventricular (LV) dysfunction and attenuates ventricular remodeling via markedly increasing FGF21 expression in a signal transducer and activator of transcription (STAT)3-dependent manner, indicating that FGF21 might be a promising therapeutic target for MI treatment (Tang et al., 2018).